The administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to normal individuals enhances hemopoietic progenitors circulating into periphThe effects of rhG-CSF on lymphocyte blastogenesis were evaluated in six healthy donors, submitted to proeral blood for subsequent collection and use for syngeneic and allogeneic transplantation (APBPCT) or for graft rejecgenitor cell mobilization for allogeneic transplantation. Neutrophil, monocyte and lymphocyte count increased tion and relapse after T cell non-depleted marrow transplants. 1, 2 In a recent survey, 3 although 1-2 logs more T 6.7-fold, 5.3-fold and 2.0-fold on day +4 of rhG-CSF as compared with baseline. The DNA stimulation index lymphocytes were routinely infused with unmanipulated peripheral blood, the incidence and severity of acute graft-(DNA SI) of 72 h phytohemagglutinin (PHA)-treated cultures decreased from 20% (15-35.5) prior to rhGversus-host disease (aGVHD) were comparable to marrow infusion, with approximately half of the patients developing CSF to 6.7% (1.5-11.9; P ‫؍‬ 0.0026), 8% (4-12; P ‫؍‬ 0.0091) and 15% (9-22; P ‫؍‬ 0.0091) on days +2, +4
A recent retrospective analysis revealed a greater inciafter and did not show any correlation with DNA SI, suggesting that it was not responsible for the observed dence of chronic GVHD and elevated TNF-␣ plasma levels in patients not receiving rhG-CSF after allogeneic marrow phenomena. Interestingly, DNA SI of PHA-treated cultures inversely correlated with IL-1ra and Lf levels.
infusion (80% as compared with 18% in recipients given rhG-CSF); 8 moreover, in vitro studies showed a down-CD3 ϩ and CD19 ϩ lymphocyte activation status, ie CD23, CD25, CD30 and HLA-DR coexpression, was not modulation of allogeneic immune responses by G-CSF via inhibition of TNF-␣ production.
affected by rhG-CSF administration. Pharmacological doses of rhG-CSF in healthy donors inhibit lymphocyte
The in vivo effects of rhG-CSF on peripheral blood lymphocytes remain controversial.
10, 11 We recently reported a blastogenesis via an increased production and/or release of immunoregulatory soluble mediators, ie IL-1ra and significant elevation of lymphocyte and monocyte count in healthy subjects receiving 16 g/kg/day rhG-CSF.
atory soluble mediators, ie IL-1 receptor antagonist (ILtration and on days +2, +4, +6 and +30. Maximum lymphocyte recruitment and proliferation in response to lectins 1ra), lactoferrin (Lf) and interleukin-10 (IL-10). In addition, interleukin-8 (IL-8) plasma levels were measured; recent occur after prolonged stimulation; 20 consequently, 250 l of unseparated heparin-anticoagulated blood were cultured investigations showed an increase of endogenous IL-8 following granulocyte-macrophage (GM)-CSF administration for 72 h at 37°C in 5% CO 2 atmosphere in mitogen-containing lyophilized culture medium, reconstituted in sterile disto healthy volunteers, responsible for sustained neutrophil activation, prolonged intravascular neutrophil circulation tilled water (Blastest; Ylem, Rome, Italy). Combined cell surface antigen and DNA staining was performed as foltime and release of Lf and elastase. 17 lows:
21 culture supernatants were removed by centrifugation at 300 g for 5 min in PBS-1%BSA and cells were incubated for 30 tration and daily for 6 consecutive days. Blood was drawn CD4
+ T cell clones with established profiles of cytokine in EDTA and plasma was separated by centrifugation (15 secretion (helper type-1 (Th1) and type-2 (Th2)), generous min at 4000 r.p.m.) shortly after collection, aliquoted and gift of G Del Prete, Florence, Italy), were used as negative stored at −80°C until used. and positive controls respectively for CD30 staining.
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Plasma concentrations of G-CSF, IL-1ra, Lf, IL-8 and IL-10 were evaluated by sensitive and specific immunoassays (R&D System, British Biotechnology, Cowley, UK).
Lymphocyte blastogenesis
The detection thresholds were 10 pg/ml for IL-1ra and IL-8, 20 ng/ml for Lf and 5 pg/ml for IL-10 and G-CSF. Each For the evaluation of lymphocyte reactivity to mitogens (PHA 5 g/ml, ConA 5 g/ml, PWM 5 g/ml), peripheral cytokine level represents the mean value observed in three separate determinations. The intra-assay variability for the blood samples were obtained prior to rhG-CSF adminis- + /CD8 + ratio was not affected (Table 1) . To test the approximation of population distribution to norActivated B and T lymphocytes, measured by their comality, y (g) statistics (for symmetry and kurtosis testing) expression of HLA-DR, CD25 and CD23 antigens, showed as well as probability plots were used. Results were asymno significant modification following rhG-CSF treatment. metrically distributed and, consequently, were presented as A minor subset (2-3%) of CD4 + T lymphocytes comedian values and interquartile ranges. Correlations were expressed HLA-DR activation antigen prior to rhG-CSF explored by Spearman rank analysis (Rs) and all comparisons were performed with Wilcoxon W test for paired determinations. The criterion for statistical significance was Table 1 Flow cytometric analysis of lymphocyte subsets in healthy defined as P р 0.05. Type-2 cytokine-producing (Th2) CD30 + CD4 + lymphocytes increased from 0.16% (0-0.3) to 0.2% (0-0.4) on day +4 of rhG-CSF administration (Figure 2b ; P = NS), suggesting that rhG-CSF did not shift peripheral lymphocyte to a Th2-like cytokine profile, at least as measured by the coexpression of CD30 antigen.
More than 98% of CD4 and CD8 T lymphocytes coexpressed CD11a leukocyte integrin prior to rhG-CSF administration and no modifications of percent CD11a + cells or CD11a staining intensity occurred during the rhG-CSF course.
Lymphocyte transformation in response to lectins can be evaluated in a standardized and reproducible manner by measuring the relative DNA content of propidium iodidestained nuclei. 16 In our study, median CVs, a reliable measure of S-phase accuracy, were always Ͻ3% in unstimulated cultures and varied from 3.9 (3.8-4.3) prior to rhG-CSF to 3.5 (2.7-4.8), 3.4 (3.2-3.7) and 3.4 (2.8-4.1) on days +2, +4 and +6, respectively.
DNA SI of PHA-treated cultures markedly decreased from 20% (15-35.5) to 6.7% (1.5-11.9, P = 0.0026), 8% (4-12, P = 0.0091) and 15% (9-22, P = 0.0091) respectively on days +2, +4 and +6 of rhG-CSF treatment. The DNA SI of PHA-treated lymphocytes from a representative subject are shown in Figure 3 . However, the addition of rhG-CSF to PHA-stimulated cultures of healthy subjects not receiving exogenous rhG-CSF did not modify the blastogenic response as evaluated in terms of percent Sphase (data not shown), suggesting that the observed in vivo inhibition of lymphocyte proliferation is not directly mediated by rhG-CSF.
Responsiveness to ConA decreased from 18% (12-20) prior to rhG-CSF to 1.8% (0.5-7; P Ͻ 0.01), 3% (2-8; P Ͻ 0.01) and 5% (2-11; P = 0.009) on days +2, +4 and +6 respectively (data not shown). No significant changes of cell cycle distribution were observed in PWM-stimulated cultures, suggesting that the B lymphocyte compartment was not affected by rhG-CSF treatment (data not shown). All modifications were completely abrogated 3 weeks after rhG-CSF discontinuation.
The DNA SI of PHA-stimulated lymphocytes showed an maximal expansion of the neutrophil and monocyte compartments, induced by rhG-CSF. 130 pg/ml to 420 pg/ml (P = 0.022), 350 pg/ml (P = 0.009) and 420 pg/ml (P = 0.0013; Figure 5 ). IL-10 levels G-CSF, IL-1ra, Lf, IL-10 and IL-8 levels increased from 5 pg/ml to 25 pg/ml on day +2 (P = NS), returned to pretreatment values thereafter and showed no G-CSF plasma levels consistently increased following exogenous rhG-CSF administration and returned to presignificant correlation with DNA SI (Rs = −0.22). IL-ra and Lf plasma levels positively correlated with treatment values 24 h after rhG-CSF discontinuation ( Figure 5 ).
neutrophil count (Rs = 0.75, P = 0.0001 and Rs = 0.67, P = 0.0003 respectively, Figure 6a and b) ; similarly, IL-1ra IL-1ra plasma concentration increased from 198.6 pg/ml to 1220 pg/ml (P = 0.0023), 2871 pg/ml (P = 0.0020) and plasma levels showed a strong correlation with monocyte count (Rs = 0.65, P = 0.0003; Figure 6c ). 2937.8 pg/ml (P = 0.0049) on days +2, +4 and +6 of rhG-CSF treatment, respectively; similarly, Lf increased from Interestingly, IL-1ra and Lf inversely correlated with DNA SI of PHA-treated cultures (Rs = −0.71, P = 0.014 liminary studies were not significantly different from T cell non-depleted allogeneic marrow infusion, although periphand Rs = −0.67, P = 0.003 respectively; Figure 4c and d) . This observation indicates that the inhibitory activity on T eral blood allografts contain 10-fold more T lymphocytes as compared with marrow allografts. 5, 6 lymphocyte blastogenesis was maximal when the biological effects of rhG-CSF were maximal (ie the increase of neuRhG-CSF exerts pleiotropic activities, including hemopoietic progenitor mobilization and enhancement of circultrophils and monocytes). The intervention of soluble mediators is further confirmed by the abrogation of the inhiating neutrophil number and effector functions. In response to rhG-CSF, newly formed neutrophils show morphological bition of lymphocyte blastogenesis in PHA-containing cultures performed in the absence of autologous plasma (data immaturity, altered light-scatter properties, 25 decreased CD16 (Fc␥III) Ag expression, enhanced capacity to pernot shown).
RhG-CSF did not induce any modification of endogenform CD64 (Fc␥l)-dependent cell cytotoxicity 26, 27 and increased expression of CD66b, CD11b (CR3) and Plous IL-8 levels which did not exceed the detection threshold value of 10 pg/ml either prior to or following rhGlinked proteins, ie leukocyte alkaline phosphatase and CD14. 28 In addition, rhG-CSF modulates effector mol-CSF administration, thus confirming the inability of G-CSF to enhance IL-8 secretion in normal volunteers. 17 ecules on peripheral blood monocytes, increasing the expression of CD35 (CR1), CD11b, CD64 and CD16 and enhancing defence against infections and tumoricidal activity in cancer patients.
10, 27 Recently, monocytes from Discussion rhG-CSF-stimulated subjects were shown to induce the secretion of IL-6 and G-CSF by marrow stromal cells. 29 RhG-CSF is currently administered to healthy donors to harvest granulocytes for therapeutic transfusions and to In murine models, Pan et al 30 reported an increase of type-2 cytokines produced by splenocytes in G-CSF-treated recruit allogeneic hemopoietic progenitors for graft rejection or leukemia in relapse after conventional marrow transmice: secretion of IL-2 and IFN-␥ respectively were abrogated or significantly decreased. In response to activating plants. [1] [2] [3] 24 The incidence and severity of aGVHD in pre- stimuli, CD4 + and CD8 + subsets released higher levels of counts inversely correlated with DNA SI of lectin-containing cultures, suggesting that rhG-CSF priming might induce IL-4 as compared with controls; recipients of G-CSFtreated splenocytes showed a more favorable engraftment the release of immunoregulatory and anti-inflammatory soluble mediators. IL-1ra and Lf markedly increased and posikinetics and improved survival from GVHD.
Recent works explored the cytokine release induced by tively correlated with neutrophil and monocyte count, indicating that their plasma levels were maximal when maximal rhG-CSF in healthy subjects: 31 rhG-CSF treatment shifted primed neutrophils toward an anti-inflammatory state, was the expansion of the neutrophil and monocyte compartments. Moreover, IL-1ra and Lf levels inversely correlated attenuating TNF-␣, IFN-␥ and GM-CSF secretion and enhancing IL-1ra, soluble TNF receptor (sTNF-R), IL-6, with DNA SI of PHA-containing cultures, suggesting that they may be responsible for the observed inhibition of lym-IL-8 and IL-10 release. 32 Moreover, a significant increase of plasma IL-1ra, TNF-␣, sTNF-R p55 and p75 has been phocyte blastogenesis; it is particularly interesting that Lf in vitro, at concentrations similar to those achieved in our recently documented in healthy subjects receiving G-CSF followed by endotoxin stimulation. 33 study after rhG-CSF administration, can inhibit lymphocyte proliferation as well as the production of inflammatory In our study, a significant increase of peripheral blood neutrophils, monocytes and lymphocytes occurred from day cytokines, ie IL-1 and TNF-␣. [34] [35] [36] The role of soluble immunoregulatory mediators in the observed phenomena +1 of rhG-CSF administration, reaching maximal expansion on day +4. The percentages of CD4 + and CD8 + T lymseems to be confirmed by the abrogation of the inhibition of lymphocyte blastogenic responses in PHA-stimulated phocytes were both significantly increased compared to baseline; the CD4/CD8 ratio was unaffected, suggesting cultures performed in the absence of autologous plasma. The existence of a neutrophil-centered cytokine network that the observed modifications of lymphocyte blastogenesis could not be solely ascribed to the expansion of the is supported by a growing body of experimental evidence: neutrophils can express mRNA for a variety of cytokines CD8 + T cell compartment. Lymphocyte reactivity to PHA and ConA declined in all and cytokine receptors, thus influencing a variety of biological activities, including immune processes. 32 subjects after the first s.c. injection of rhG-CSF (16 g/kg/day) and returned to pretreatment values 3 weeks Lf is a major iron-binding protein stored in neutrophil secondary granules; plasma Lf levels depend on the magniafter rhG-CSF discontinuation. Neutrophil and monocyte tude of neutrophil degranulation and increase in iron overload, inflammatory states, infectious diseases and tumor development. Lf plays a pivotal role in defense mechanisms via its immunomodulatory functions, ie (1) inhibition of antibody synthesis and release of TNF, IL-1␤ and IL-2; (2) increase of NK cell cytotoxicity; (3) suppression of mitogen and antigen-induced human lymphocyte proliferation. [34] [35] [36] IL-1ra is a competitive inhibitor of IL-1 agonist activity, interacting avidly both with membrane-bound and with soluble forms of IL-1 receptors.
37,38 IL-1ra is released by monocytes and neutrophils and G-CSF administration in healthy donors has been shown to enhance IL-1ra production by several-fold in response to stimulation with lipopolysaccharide or endotoxin. 31, 33 Recently, van Pelt et al 17 described the effects of a single administration of GM-CSF on neutrophil activation and cytokine plasma levels in normal volunteers. Unlike G-CSF, GM-CSF induced the systemic release of IL-8, leading to pronounced neutrophil activation and Lf release and to a prolonged intravascular neutrophil circulation time; no changes of lymphocyte count were observed following GM-CSF administration. In our study, no increase of endogenous IL-8 occurred, indicating no role of IL-8 in neutrophil activation, enhanced survival and cytokine release after G-CSF administration; further investigations are in progress to evaluate the effects of GM-CSF on lymphocyte number and function in healthy subjects.
Human IL-10 is a type-2 cytokine produced by CD4 + T cells, activated CD8 + T cells and by monocytes; IL-10 inhibits proliferation in primary mixed lymphocyte culture and decreases the production of several cytokines by activated mononuclear cells, acting as a potent immunosuppressive factor. 39 In addition, IL-10 has been shown to promote the synthesis and release of IL-1ra and to suppress the secretion of TNF-␣ and IL-1␤ by human neutrophils. 32 In our study, although a five-fold increase of endogenous IL-10 occurred on day +2 compared to pretreatment values, IL-10 plasma levels did not correlate with DNA-SI, suggesting that IL-10 secretion probably does not account for the down-regulation of lymphocyte blastogenesis.
In all donors studied, lymphocyte activation status remained unaffected by rhG-CSF treatment; the ex vivo expression of CD25, CD23 and HLA-DR activation antigens on CD4
+ and CD19 + lymphocytes did not change during rhG-CSF course compared with pretreatment levels.
The CD11/CD18 leukocyte integrins consist of three heterodimers involved in a variety of cell-matrix and cell-cell adhesion functions, including mitogen-and antigen-induced proliferation, T cell-mediated cytotoxicity and B cell immunoglobulin production. 40 Interestingly, no modifications of CD11a expression on T lymphocytes, either in terms of percent positive cells or staining intensity, occurred in any subject during rhG-CSF course, suggesting that the altered lymphocyte response to lectin mitogens could not be ascribed to a defect of surface expression of 
